Get started
Century Therapeutics, Inc.Century Therapeutics, Inc.Century Therapeutics, Inc.

Century Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

IPSC chart


Full chart

IPSC upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪62.08 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.8572 USD
Net income (FY)
‪−136.67 M‬ USD
Revenue (FY)
‪2.23 M‬ USD
Shares float
‪36.06 M‬
Beta (1Y)
2.72

Employees


Employees (FY)
165
Change (1Y)
+2 +1.23%
Revenue / Employee (1Y)
‪13.55 K‬ USD
Net income / Employee (1Y)
‪−828.32 K‬ USD

About Century Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Brent Pfeiffenberger
Website
centurytx.com
Headquarters
Philadelphia
Founded
2018
FIGI
BBG00PM8N5W0
Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It focuses on harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

IPSC news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where IPSC is featured.

See all sparks 

Frequently Asked Questions


The current price of IPSC is 0.7301 USD — it has decreased by −2.51% in the past 24 hours. Watch Century Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Century Therapeutics, Inc. stocks are traded under the ticker IPSC.
IPSC stock has fallen by −4.67% compared to the previous week, the month change is a −21.49% fall, over the last year Century Therapeutics, Inc. has showed a −82.24% decrease.
We've gathered analysts' opinions on Century Therapeutics, Inc. future price: according to them, IPSC price has a max estimate of 13.00 USD and a min estimate of 4.00 USD. Watch IPSC chart and read a more detailed Century Therapeutics, Inc. stock forecast: see what analysts think of Century Therapeutics, Inc. and suggest that you do with its stocks.
IPSC reached its all-time high on Aug 17, 2021 with the price of 32.8990 USD, and its all-time low was 0.6810 USD and was reached on Feb 11, 2025. View more price dynamics on IPSC chart.
See other stocks reaching their highest and lowest prices.
IPSC stock is 5.61% volatile and has beta coefficient of 2.72. Track Century Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Century Therapeutics, Inc. there?
Today Century Therapeutics, Inc. has the market capitalization of ‪62.08 M‬, it has decreased by −8.22% over the last week.
Yes, you can track Century Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Century Therapeutics, Inc. is going to release the next earnings report on Mar 13, 2025. Keep track of upcoming events with our Earnings Calendar.
IPSC earnings for the last quarter are −0.37 USD per share, whereas the estimation was −0.45 USD resulting in a 17.91% surprise. The estimated earnings for the next quarter are −0.41 USD per share. See more details about Century Therapeutics, Inc. earnings.
Century Therapeutics, Inc. revenue for the last quarter amounts to ‪791.00 K‬ USD, despite the estimated figure of ‪440.00 K‬ USD. In the next quarter, revenue is expected to reach ‪784.43 K‬ USD.
IPSC net income for the last quarter is ‪−31.23 M‬ USD, while the quarter before that showed ‪−31.21 M‬ USD of net income which accounts for −0.06% change. Track more Century Therapeutics, Inc. financial stats to get the full picture.
No, IPSC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 23, 2025, the company has 165.00 employees. See our rating of the largest employees — is Century Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Century Therapeutics, Inc. EBITDA is ‪−119.04 M‬ USD, and current EBITDA margin is ‪−5.02 K‬%. See more stats in Century Therapeutics, Inc. financial statements.
Like other stocks, IPSC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Century Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Century Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Century Therapeutics, Inc. stock shows the sell signal. See more of Century Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.